238
Participants
Start Date
September 8, 2009
Primary Completion Date
November 12, 2011
Study Completion Date
November 12, 2011
Ataluren
Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
Placebo
Placebo matching to ataluren will be provided.
Beth Israel Medical Center, New York
New York Medical College, Valhalla
Childrens Hospital of Pittsburgh, Pittsburgh
Johns Hopkins Children's Center, Baltimore
University of North Carolina, Chapel Hill
Emory University Cystic Fibrosis Center, Atlanta
Hôpital des Enfants, Toulouse
University of Miami, Miami
Miami Children's Hospital, Miami
University of Alabama-Birmingham, Birmingham
Rainbow Babies & Children's Hospital, Cleveland
University of Iowa, Iowa City
Children's Memorial Hospital, Chicago
Washington University, St Louis
University of Texas, Tyler
The Children's Hospital, Aurora
Miller Children's Hospital Long Beach, Long Beach
Hadassah University Hospital - Mount Scopus, Jerusalem
Rady Children's Hospital - San Diego, San Diego
Lucile Packard Children's Hospital, Palo Alto
Stanford, Palo Alto
University of Washington, Seattle
Children's Hospital Boston, Boston
Hôpital Erasme, Brussels
Hôpital Universitaire des Enfants Reine Fabiola, Brussels
University Hospital Brussels, Brussels
University Hospital Leuven, Leuven
University of Toronto, Toronto
Hôpital Cochin, Paris
Hôpital Necker - Enfants Malades, Paris
Klinikum der Universität Köln, Cologne
Università La Sapienza, Rome
Azienda Ospedaliera di Verona, Verona
Universitair Medisch Centrum Utrecht, Utrecht
Hospital Universitario La Paz, Madrid
Karolinska University Hospital, Huddinge, Stockholm
Belfast City Hospital, Belfast
Alder Hey Children's Hospital, Liverpool
Lead Sponsor
Cystic Fibrosis Foundation
OTHER
PTC Therapeutics
INDUSTRY